High concentration white blood cells as a therapeutic product

• US 7,169,547 B2
• Filed: 05/15/2001
• Issued: 01/30/2007
• Est. Priority Date: 12/05/1994
• Status: Expired due to Term

• Current Assignee: New York Blood Center Incorporated
• Original Assignee: New York Blood Center Incorporated
• Inventors: Rubinstein, Pablo, Stevens, Cladd E., Coelho, Philip Henry
• Primary Examiner(s): Bianco; Patricia
• Application Number:
  US09/855,789
• Publication Number:
  US 20010034513A1
• Time in Patent Office: 2,086 Days
• Field of Search: 604/4.01, 604 501- 504, 604/6.01, 604/6.03, 604/406, 604/409, 604/410, 604/403, 604/408, 604/903, 128/898, 424/93.1, 424/93.7, 424/93.71, 424/520, 424/529, 424530-534, 424/937, 435/2, 435/810, 435/1, 435/1.3, 435/4, 435/5, 435/7.22, 435/7.25, 435176- 77, 435/174, 435/29, 435/180, 62/62, 422/44, 422 40- 41, 210/600, 210/767, 210781- 82, 514/2, 514/4, 514/513, 514/563, 514/570, 436/18, 600/34, 536/1.11, 568/892, 530362- 63
• US Class Current: 435/2
• CPC Class Codes: A01N 1/02 Preservation of living parts
• CPC Class Codes: A01N 1/0263 Non-refrigerated containers specially adapted for transporting or storing living parts whilst preserving, e.g. cool boxes, blood bags or "straws" for cryopreservation
• CPC Class Codes: A61J 1/12 with means for holding samples of contents
• CPC Class Codes: A61K 35/14 Blood; Artificial blood perfluorocarbons A61K31/02; umbilical cord blood A61K35/51; haemoglobin A61K38/42
• CPC Class Codes: A61M 1/0209 Multiple bag systems for separating or storing blood components
• CPC Class Codes: A61M 1/0236 with sampling means, e.g. sample bag or sampling port
• CPC Class Codes: A61M 1/0272 Apparatus for treatment of blood or blood constituents prior to or for conservation, e.g. freezing, drying or centrifuging
• CPC Class Codes: A61M 1/0281 Apparatus for treatment of blood or blood constituents prior to transfusion, e.g. washing, filtering or thawing
• CPC Class Codes: A61M 1/3693 using separation based on different densities of components, e.g. centrifuging
• CPC Class Codes: A61M 2202/0071 product to be retained or harvested, e.g. by pheresis
• CPC Class Codes: A61M 2202/0439 White blood cells; Leucocytes lymphocytes A61M2202/0407
• CPC Class Codes: A61M 2202/0462 Placental blood, umbilical cord blood

Abstract

A therapeutic product formed from a high concentration of white blood cells having a high degree of cell viability. The white blood cells are sequestered from their normal population presence in whole blood by placing the blood into a container and preventing coagulation of the blood, separating the blood into two components, one of which is extremely rich in white blood cells through the use of a reagent and centrifugation, sequestering the white cell concentration, and freezing the white cells.

Claims

1. A therapeutic product separated from a sample of cord blood or placental blood, wherein the therapeutic product consists essentially of at least 80% of white blood cells contained in the sample of cord blood or placental blood, less than all of plasma contained in the sample of cord blood or placental blood, less than 10% of red blood cells contained in the sample of cord blood or placental blood, and a red blood cell sedimentation reagent that facilitated separation of the red blood cells from the white blood cells contained in the sample of cord blood or placental blood, and wherein the therapeutic product has a volume of 10 milliliters to 20 milliliters.

2. The therapeutic product of claim 1, wherein the therapeutic product further consists of a cryoprotectant.

3. The therapeutic product of claim 2, wherein the cryoprotectant comprises dimethyl sulfoxide.

4. The therapeutic product of claim 2, wherein the cryoprotectant comprises dextran.

5. The therapeutic product of claim 1, wherein the therapeutic product further consists of an anticoagulant.

6. The therapeutic product of claim 5, wherein the anticoagulant comprises Citrate, Phosphate, and Dextrose (CPD).

7. The therapeutic product of claim 1, wherein the therapeutic product has an osmolarity of not more than 300 milliosmols.

8. The therapeutic product of claim 1, wherein the red cell to white cell count is approximately one hundred (100) to one (1).

9. A therapeutic product separated from a sample of cord blood or placental blood, wherein the therapeutic product comprises at least 80% of white blood cells contained in the sample of cord blood or placental blood, less than all of plasma contained in the sample of cord blood or placental blood, less than 10% of red blood cells contained in the sample of cord blood or placental blood, a red blood cell sedimentation reagent that facilitated separation of the red blood cells from the white blood cells contained in the sample of cord blood or placental blood, and dimethyl sulfoxide diluted to 50% with dextran.

10. A therapeutic product separated from a sample of cord blood or placental blood, wherein the therapeutic product comprises at least 80% of white blood cells contained in the sample of cord blood or placental blood, less than all of plasma contained in the sample of cord blood or placental blood, and a red blood cell sedimentation reagent that facilitated separation of the red blood cells from the white blood cells contained in the sample of cord blood or placental blood, and wherein the red cell to white cell count is approximately one hundred (100) to one (1).